Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Covid19
Interventions: theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor; Drug
Lead sponsor: Matthew Neal MD; Other
Eligibility: 18 Years and older
Enrollment: 3,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 81
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Rhinitis, Allergic, Perennial, Hay Fever
Interventions: Ciclesonide nasal, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease
Interventions: Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells, Standard of care; Biological · Other
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 41
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 38 more

Conditions: Influenza, Human
Interventions: BPL-1357 IM, BPL-1357 IN, Placebo IM, Placebo IN; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Bethesda, Maryland • Galveston, Texas

Conditions: Ulcerative Colitis
Interventions: Budesonide MMX®, Placebo, 5-ASA; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 39
States / cities: Anaheim, California • Lakewood, California • San Diego, California + 36 more

Conditions: Fibrillation, Atrial, Atrial Fibrillation
Interventions: SB424323; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Mobile, Alabama • Troy, Michigan • Akron, Ohio + 6 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 2,734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 100
States / cities: Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 79 more

Conditions: Friedreich's Ataxia
Interventions: GV101, Placebo; Drug
Lead sponsor: Graviton Bioscience Corporation; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Shock,Hemorrhagic
Interventions: Valproic Acid, Isotonic saline solution; Drug
Lead sponsor: Dr. Hasan Alam; Other
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Uremic Pruritus, Pruritus
Interventions: nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tablets 120mg BID, Placebo tablets BID; Drug
Lead sponsor: Trevi Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more

Conditions: Subarachnoid Hemorrhage, Aneurysmal
Interventions: EG-1962 (nimodipine microparticles), Enteral Nimodipine; Drug
Lead sponsor: Edge Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Phoenix, Arizona • San Francisco, California • Baltimore, Maryland

Conditions: Healthy
Interventions: PF-06946860, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Refractory Chronic Cough
Interventions: 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]; Drug
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida

Conditions: Obesity, Inflammation
Interventions: Yogurt, Control food; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Benign Prostatic Hyperplasia
Interventions: S-equol, Placebo; Drug
Lead sponsor: Ausio Pharmaceuticals, LLC; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 5
States / cities: Huntsville, Alabama • Aventura, Florida • Clearwater, Florida + 2 more

Conditions: Critical Limb Ischemia
Interventions: HGF Plasmid (AMG0001), Matching Placebo; Biological
Lead sponsor: AnGes USA, Inc.; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 28
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 23 more

Conditions: Chemotherapy-Induced Nausea and Vomiting
Interventions: Netupitant and Palonosetron, Palonosetron, Dexamethasone; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 1,455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 28
States / cities: Anniston, Alabama • Muscle Shoals, Alabama • Hot Springs, Arkansas + 24 more

Conditions: Generalized Myasthenia Gravis
Interventions: Iptacopan, Matching Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 13
States / cities: Scottsdale, Arizona • Fullerton, California • Sacramento, California + 10 more

Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 59
States / cities: Mobile, Alabama • Gilbert, Arizona • Mesa, Arizona + 53 more

Conditions: Bipolar Depression, Major Depressive Disorder
Interventions: Lumateperone, Placebos; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 13
States / cities: Garden Grove, California • Oceanside, California • Sherman Oaks, California + 10 more

Conditions: Treatment Resistant Depression
Interventions: Psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 62
States / cities: Gilbert, Arizona • Bellflower, California • Encino, California + 50 more

Conditions: Work-related Injury
Interventions: Front Line Worker Pilot Project; Other
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Older, Adults, Older Adults, Balance
Interventions: restricted vision (no-V), full vision (full-V); Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 65 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy Participants Study
Interventions: AZD0292, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

BPL-1357 Against H1N1 Influenza Virus Challenge

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

GV101 for Friedreich's Ataxia (FA) Treatment

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Yogurt for Prevention of Chronic Inflammation

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Organizational Approaches to TWH for Low-Income Workers

Postural Control in Adults

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants